The challenge of polypharmacy in cardiovascular medicine.

  title={The challenge of polypharmacy in cardiovascular medicine.},
  author={Massimo Volpe and Diana Hsien-jen Chin and Francesco Paneni},
  journal={Fundamental & clinical pharmacology},
  volume={24 1},
Albeit great efforts in reducing the burden of cardiovascular diseases (CVD), their prevalence continues to grow worldwide. Among the causes for this rising burden, the upcoming pandemic of obesity and diabetes further enhances the estimates of CV mortality and healthcare costs over the next decades. Nevertheless, advances in CVD treatment has increased life-expectancy, and future perspectives announce a growing aging population, with increasing comorbid conditions predisposing to CVD. Despite… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 21 extracted citations


Publications referenced by this paper.
Showing 1-10 of 74 references

Effects of a polypill ( Polycap ) on risk factors in middle - aged individuals without cardiovascular disease ( TIPS ) : a phase II , double - blind , randomised trial . Indian polycap study ( TIPS )

S. Yusuf, P. Pais, R. Afzal
Lancet • 2009

Effect of n - 3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI - HF trial ) : a randomised , double - blind , placebo - controlled trial . Gissi - HF Investigators

L. Tavazzi, P. MaggioniA., R. Marchioli
Lancet • 2008

Metabolic syndrome pandemic

M. GrundyS.
Arterioscler . Thromb . Vasc . Biol . • 2008

Relationship between polypharmacy and underprescribing . ; OLDY ( OLd people Drugs & dYsregulations ) study group

A. KuijpersM., J. vanMarumR., C. EgbertsA., A. JansenP.
Br . J . Clin . Pharmacol . • 2008

Similar Papers

Loading similar papers…